Consultant Medicine Development Lead, ENA Respiratory
| Role | Organisation | Sources |
|---|---|---|
| GlaxoSmithKline | Brandon Capital portfolio (Tue 22 Jun 2021), Brandon Capital portfolio (Wed 16 Jun 2021), Brandon BioCatalyst portfolio | |
| Board of Directors (former) | ENA Respiratory | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Consultant Medicine Development Lead | ENA Respiratory | Uniseed |
| Medicine Development Leader (former) | ENA Respiratory | Brandon Capital, Brandon BioCatalyst, Brandon Capital portfolio (Tue 22 Jun 2021), Brandon Capital portfolio (Wed 16 Jun 2021), Brandon BioCatalyst portfolio |
| President and Chief Scientific Officer (former) | US COPD Foundation | Brandon Capital portfolio (Tue 22 Jun 2021), Brandon Capital portfolio (Wed 16 Jun 2021), Brandon BioCatalyst portfolio (Wed 16 Jun 2021), Brandon Capital portfolio (Tue 15 Jun 2021), Brandon BioCatalyst portfolio (Tue 15 Jun 2021) |
| Vice President of Medical Innovation (former) | GSK Pharmaceuticals | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Ruth Tal-Singer. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.
Australian biotech ENA Respiratory raised funding led by Brandon Capital and Minderoo Foundation to advance its Covid-19 nasal spray toward the clinic, and appointed Ruth Tal-Singer to its board.
ENA Respiratory secured up to AU$32 million, co-led by Brandon Capital Partners and Minderoo Foundation with Uniseed, to advance its INNA-051 nasal spray, and appointed Ruth Tal-Singer to its board.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·SmartCompany